Skip to main content
Erschienen in: Thrombosis Journal 1/2015

Open Access 01.12.2015 | Review

Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk

verfasst von: Elena N Lipets, Fazoil I Ataullakhanov

Erschienen in: Thrombosis Journal | Ausgabe 1/2015

Abstract

Thrombosis is a deadly malfunctioning of the hemostatic system occurring in numerous conditions and states, from surgery and pregnancy to cancer, sepsis and infarction. Despite availability of antithrombotic agents and vast clinical experience justifying their use, thrombosis is still responsible for a lion’s share of mortality and morbidity in the modern world. One of the key reasons behind this is notorious insensitivity of traditional coagulation assays to hypercoagulation and their inability to evaluate thrombotic risks; specific molecular markers are more successful but suffer from numerous disadvantages. A possible solution is proposed by use of global, or integral, assays that aim to mimic and reflect the major physiological aspects of hemostasis process in vitro. Here we review the existing evidence regarding the ability of both established and novel global assays (thrombin generation, thrombelastography, thrombodynamics, flow perfusion chambers) to evaluate thrombotic risk in specific disorders. The biochemical nature of this risk and its detectability by analysis of blood state in principle are also discussed. We conclude that existing global assays have a potential to be an important tool of hypercoagulation diagnostics. However, their lack of standardization currently impedes their application: different assays and different modifications of each assay vary in their sensitivity and specificity for each specific pathology. In addition, it remains to be seen how their sensitivity to hypercoagulation (even when they can reliably detect groups with different risk of thrombosis) can be used for clinical decisions: the risk difference between such groups is statistically significant, but not large.
Hinweise

Competing interest

FA is an employee and a founder of HemaCore LLC that holds several patents on the use of spatial clot growth dynamics for blood clotting diagnostics, and develops the spatial clot growth assay under the trade name of Thrombodynamics.

Authors’ contributions

EL collected and analyzed literature data, wrote the paper. FI wrote the paper, revised it critically, have given final approval of the version to be published. All authors read and approved the final manuscript.
Abkürzungen
APTT
Activated partial thromboplastin time
AT
Antithrombin
CP
Cancer procoagulant
DIC
Disseminated intravascular coagulation
DVT
Deep venous thrombosis
ETP
Endogenous thrombin potential
F1 + 2
Prothrombin activation fragments
HR
Hazard ratio
INR
International normalized ratio
MP
Microparticles
NET
Neutrophil extracellular traps
PAI-1
Plasminogen activator inhibitor type 1
PC
Protein C
PPP
Platelet poor plasma
PS
Protein S
PT
Prothrombin time
ROTEM
Rotational thromboelastometry
RR
Relative risk
TAT
Thrombin-antithrombin complex
TEG
Thromboelastography
TF
Tissue factor
TFPI
Tissue factor pathway inhibitor
TM
Thrombomodulin
tPA
Tissue plasminogen activator
VLDL
Very low density lipoproteins
VT
Venous thrombosis
VTE
Venous thromboembolism
vWF
Von Willebrand factor

Introduction

Thrombotic complications occur in many cases: they accompany or even induce innumerable disorders and states: atherosclerosis, infarction, stroke, pregnancy, trauma, surgery, sepsis, etc. Their danger is presently well recognized, and there are regulations on the use of antithrombotic agents for all patients with thrombotic risks. Such agents are presently available in a huge variety [1] and include direct and indirect coagulation factors inhibitors, antagonists of platelet activation and adhesion receptors, and also of platelet signaling.
However, there are unmet needs with regard to identification the patients at risk of thrombosis, individual selection and correct dosing of these drugs, in particular for individual patients. There is always risk of bleeding (1-3% for all antithrombotics at their recommended doses), and brain hemorrhage can be no less fatal than thrombosis. Traditional coagulation assays are insensitive to hypercoagulation and unable to evaluate thrombotic risks.
A possible solution is proposed by use of global, or integral, assays [2-4] that aim to mimic and reflect the major physiological aspects of hemostasis process in vitro. Here we review the existing evidence regarding the ability of both established and novel global assays (thrombin generation, thrombelastography, thrombodynamics, flow perfusion chambers) to evaluate thrombotic risk in specific disorders. The biochemical nature of this risk and its detectability by analysis of blood state in principle are also discussed.

Pathophysiology of hypercoagulation and thrombosis

Before speaking about thrombosis risk evaluation and prediction of thrombosis using in vitro diagnostics, it is essential to discuss the biochemical nature of thrombus formation.

Venous thrombosis

Recent reviews on the venous thrombosis pathogenesis can be found in [5,6]. The basic principles of it were formulated by Virchov in 1859, who defined origin of thrombosis in his famous triad of disorders in blood composition, flow velocity or vascular wall. It is well established that venous thrombi are formed mostly as a result of fibrin formation (so-called ‘red’ thrombi rich in fibrin and entrapped red blood cells) with little if any contribution from platelet adhesion. It is not completely clear, however, how this process is triggered. Venous thrombi are attached to the vessel wall by fibrin [7], and in most cases the wall remains undamaged [8]. The most likely mechanism of triggering thrombosis involves endothelial activation. Upon blood flow stagnation, inflammation and/or hypoxia endothelial cells release the Weibel-Palade bodies containing von Willebrand factor (vWF) of increased length and P-selectin. The release enable attachment of platelets, monocytes, neutrophils [9] and their microparticles. Activated by hypoxia, cytokines, and lipopolysaccharides monocytes express Tissue factor (TF) [10], which stimulates clotting activation. Additional tissue factor is provided by microparticles derived from monocytes, cancer cells [11] and probable neutrophiles [9] depending on the primary disorder. Essential role can be played by contact activation from neutrophil extracellular traps (NET), extracellular chromatin fibers with a backbone of histones [9]; contribution of platelet- and endothelium-derived microparticles is possible [12]. Depending on the balance between procoagulant factors, their inhibitors and fibrinolysis, this endothelium activation might develop into full-scale thrombosis.

Arterial thrombosis

Arterial thrombosis is usually triggered by rupture of an atherosclerotic plaque. This leads to externalization of collagen, TF and vWF. As a result of rapid flow velocity in arteries, the primary driving mechanism of arterial thrombosis is platelet deposition with fibrin formation playing a secondary, thrombus-stabilizing role [13,14]. This is confirmed by predominance of platelets in such thrombin (so-called ‘white’ thrombi) and by efficiency of antiplatelet agents [15]. Altered platelet adhesion and aggregation due to increased vWF concentration, decreased ADAMTS13 (a metalloproteinase, that cleaves vWF to smaller, less procoagulant forms), increased in vitro platelet aggregation after low concentrations of adenosine diphosphate and/or epinephrine (sticky platelet syndrome) are associated with arterial thrombosis [16,17].
However, there are indications of hypercoagulation state in the plasma of patients suffering from arterial thrombosis: circulating factors XIa and TF were detected in patients following ischemic cerebrovascular events [18], in stable angina patients [19], in patients with systolic heart failure due to ischemic cardiomyopathy [20]. In some of the intravital arterial thrombosis animal models monocyte- and endothelium-derived microparticles were deposited in thrombi [11]. Even double-drug antiplatelet therapy in acute coronary syndrome does not prevent a ~10% yearly risk of a recurrence, while addition of rivaroxaban significantly decreases the risk [21]. These data indicate that blood coagulation contribution in arterial thrombosis should not be neglected.

Microvascular thrombosis

Originally, pathogenesis of thrombosis was primarily studied in large blood vessels. However, there has been a recent shift in the attention to the microvasculature and to the microcirculatory occlusion [22]. Probably, an important factor in this shift is that the most informative experimental models of thrombosis are microvascular ones [23]. Development of microthrombosis is usually related to TF expression by various cells, degradation of TFPI by neutrophil elastase, fXII activation by NETs released by neutrophils and enhanced by their interaction with platelets [24]. It is observed in multiple diseases (sepsis [25], cancer [26], infarction [27], thrombotic thrombocytopenic purpura [28]) and is a critical factor in the development of disseminated intravascular coagulation and organ dysfunction [29]. Among all types of thrombosis, microvascular thrombosis is most of all associated with plasma ability to coagulate overall increase, hypercoagulability [30].

Specific causes of hypercoagulation

Hypercoagulation state, usually meaning increased tendency of blood to clot, can be induced by numerous molecular mechanisms enumerated below.
Hypercoagulation in cancer is usually associated with expression of TF, cancer procoagulant (CP) and adhesion molecules. TF expression is induced by activation of oncogenes or inactivation of tumor suppressor genes [31]. Some of the circulating TF is associated with microparticles [32,33] that also accelerate clotting by providing additional phosphatidylserine. CP is a cysteine protease with factor X activating properties [34]. Its role as a factor predictive of clinical thrombosis has not been successfully demonstrated. Mice models demonstrated that NETs also contribute significantly to hypercoagulation in cancer [35]. Adhesion molecules allow direct interaction of tumor cells with endothelium, platelets, and leukocytes, can induce formation of platelet microthrombi [36].
Normal pregnancy is associated with increase in fibrinogen (Fg), Factors VII, VIII, X, and VWF. Free protein S is decreased secondary to increased levels of its binding protein, the complement component C4b. Plasminogen activator inhibitor type 1 (PAI-1) levels increase 5-fold [37]. Levels of PAI-2, produced by the placenta, increase dramatically during the third trimester [38]. For some complication of pregnancy, increased concentration of endothelial-derived and TF-positive microparticles was reported [39,40].
Hormonal contraceptives increases concentrations of Fg, prothrombin (factor II) and factors VII, VIII and X, and reduction in coagulation inhibitors, such as antithrombin (AT) and protein S and tissue factor pathway inhibitor (TFPI). On the other hand, fibrinolysis is also stimulated: tissue plasminogen activator (tPA) activity is increased, while that of PAI-1 is decreased [41].
Diabetes leads to increase in adhesion and aggregation of platelets, as well as platelet-dependent thrombin formation. Changes in the platelet reactivity occur at the stage of megakariopoiesis. Leukocytes are also activated and expose aminophospholipids and TF, express adhesive molecules that promote interaction of leukocytes with endothelium and formation of leukocyte-platelet aggregates. Dysfunction of endothelium is observed. Concentrations of VWF, factor VII, and Fg are increased, those of AT, PC, endothelial thrombomodulin (TM) are decreased. Platelets, monocytes, endothelium demonstrate increased microparticle production. Levels of PAI-1 and tPA are decreased [42].
To summarize, there are several immediate reasons of high risk systemic thrombosis. First, there are materials that directly activate coagulation: circulating contact pathway-activating microparticles [43], circulating TF on cells or microparticles (in cancer or diabetes), factor XIa (ischemic cerebrovascular events, stable angina), сancer procoagulant, bacteria. The second category includes mechanisms that do not initiate clotting by themselves but may promote clotting propagation by shifting coagulation balance: increased level, activity or longevity of pro-coagulant factors (congenital, pregnancy, oral contraceptives, mutations like prothrombin G20210A [44] or factor V Leiden [45,46]), decreased concentration or function of the anti-coagulant molecules (congenital or consumptive deficiency of AT, PS, PC [47,48]), decreased fibrinolysis, ADAMTS13, increased vWF [16]. The data for several protrombotic states discussed in this article are summarized in Table 1, which attempts to relate mechanism of pro-coagulant changes, disorders that cause them, and the types of thrombosis supported by them.
Table 1
The reasons of hypercoagulation in different states associated with risk of thrombosis discussed in the article
Background state
Activating material
Increased level of procoagulant zymogens
Decreased level of coagulation inhibitors
Fibrinolysis abnormalities
Other hemostasis abnormalities
Type of thrombosis
Cancer
ТF, NET, MP
   
Сancer procoagulant, adhesive molecules
Venous thrombosis
Pregnancy
TF, МР
Fg, VII, VIII, X
Free protein S
PAI-1↑, PAI-2↑
Thrombocytopenia, platelets activation, VWF↑
Venous thrombosis, Arterial thrombosis
Oral contraceptives
 
Fg, II, VII, VIII, X
ATIII, PS, TFPI
tPA↑, PAI-1↓
 
Venous thrombosis
Diabetes mellitus
TF, platelet, monocyte, endothelial МP
Fg, II, V, VII, VIII, and X
ATIII, PC, endothelial ТМ
PAI-1↑, tPA↑
Enhanced platelet adhesion, aggregation, leukocyte activation, VWF↑
Arterial thrombosis, Venous thrombosis?

Detection of hypercoagulability: possible strategies

Nature of pre-disposition of an individual to thrombosis may be either local or global. Local factors such as vessel wall damage, atherosclerotic plaque formation or blood flow stagnation remain naturally beyond functional laboratory assays of coagulation (although possibility to detect some markers of inflammation and damage in blood indirectly cannot be excluded). Other thrombotic events can be directly associated with global changes in blood composition. These systemic pro-thrombotic changes are called hypercoagulation. When thrombosis can be directly linked to hypercoagulability, several ways to determine it exist.
One way is to detect the specific cause: change in the coagulation factor or coagulation inhibitor concentration, presence of a circulating active factor, microparticles, change in fibrinolysis factor, vWF concentrations. While such research is important, these parameters appear to be innumerable and some of them (e.g. picomolar concentrations of factors) are extremely hard to measure. In addition, isolated information about specific causes does not give an idea about overall tendency of the blood to form thrombi.
Another strategy is to use molecular markers of ongoing thrombosis: D-dimers, fibrinopeptides, soluble fibrin monomers, thrombin-antithrombin complexes or prothrombin fragments. This strategy is used widely and has tremendous clinical advantages, but its major drawback is that it detects traces of coagulation that already occurred or goes presently at full rate. In disseminated intravascular coagulation (DIC), you may have great D-dimer in conjunction with zero clotting due to coagulopathy.
Finally, the natural way to determine hypercoagulation is to carry out coagulation experiments under conditions, where contribution of the hypercoagulation factors is significant (i.e. under conditions close in vivo). It turns out that it is not significant for the traditional clotting assays: when you stimulate clotting with huge concentrations of activators in APTT and PT, contribution of the small quantities of circulating active factors is not essential.
The possible solution to this might be global, or integral, assays of hemostasis [2-4]). They aim to mimic (patho)physiogical processes with greater accuracy and to involve all relevant processes, so they tend to determined overall hemostatic potential. Importantly, these assays usually involve low activator concentration (thrombin generation, TEG) or localization of the activator on the chamber wall (thrombodynamics, flow perfusion chambers). This could indeed make them sensitive to low concentrations of circulating agonists.
The purpose of the present review is to inventory the available data in order to test the existing claim of the global assays on their ability to predict thrombosis.

APTT and INR: are they indeed inappropriate as global assays?

Till the present times, initial evaluation of hemostatic status is done using APTT and INR assays. They are sensitive, first of all, to deficiencies of coagulation factors that usually result in their prolongation. Shortening of clot times is rare and is often attributed to pre-analytical errors (that play a great role in diagnostics, as it is very easy to induce hypercoagulation by insufficiently careful handling of whole blood). When dealing with thrombosis INR application is usually limited to assess the effectiveness of vitamin K doses [49].
However, there are reports that some thrombotic disorders may be detected by changes in APTT. Mina et al. demonstrated that APTT shortening reliably indicates abnormal factors V, XI, XII, VWF antigen and collagen-binding activity, and the level of procoagulant phospholipids, as assessed using a novel assay procedure (XACT) [50]. It is not clear whether factor VIII increase can shorten APTT. APTT shortening has also been associated with high levels of biochemical markers of thrombin generation and fibrin deposition such as prothrombin fragment 12, thrombin-antithrombin complex, and D-dimer [51]. Tripodi et al showed that shortened APTT is a risk factor for deep vein thrombosis. In patients who had an APTT ratio (coagulation time of test-to-reference plasma) smaller than the fifth percentile of the distribution in controls, the odds ratio (OR) for VTE was 2.4 and was independent of inherited thrombophilic abnormalities. Median APTT ratio values were 0.97 (range: 0.75-1.41) for patients and 1.00 (range: 0.72-1.33) for controls (P < .001) [52]. Prospective observation of a large group (918 patients) with spontaneous venous thrombosis revealed that APTT ratio was significantly longer in patients without thrombosis recurrence (0.97 ± 0.09 vs. 0.93 ± 0.09, P < 0.001) The relative risk (RR) of recurrence among patients with a APTT ratio or < 0.95 was 1.7 [53]. Legnani et al. discovered that venous thrombosis recurrence risk after cancelling anticoagulation was more than twofold higher in patients with ratio < or =0.90 versus those of the reference category (Relative risk (RR): 2.38) [54]. The data indicating predictive value of APTT are given in Table 2.
Table 2
Examples of АPPT ratio response to different procoagulant states
Procoagulant state
Number of patients in study group
Data range in control group, mean ± SD unless otherwise indicated
Data range in group with hypercoagulation, mean ± SD unless otherwise indicated
Significance
Predictive value
Reference
Comments
VTE
605 patients, 1290 - controls
Median(range) 1.00(0.72-1.33)
Median(range) 0.97(0.75-1.41)
<0.001
APTT ratio < 0.87 OR = 2.4
[52]
Retrospective study.
Recurrence after first unprovoked VTE
918 with a first VTE 101 – with recurrence
0.97 ± 0.09
0.93 ± 0.09
0.001
APTT ratio < 0.95 RR = 1.79
[53]
Prospective study. Analysis was performed 3 weeks after after completion of anticoagulant therapy.
Recurrence after first unprovoked VTE
628 with a first VTE, 71 – with recurrence
   
APTT ratio < 0.90 RR = 2.38 compared with APTT ratio > 1.05
[54]
Prospective study. Analysis wasperformed 3-4 weeks after after completion of anticoagulant therapy.
Type 2 diabetes mellitus
60 patients, 57 controls
Median(range) 0.93 (0.71–1.34)
Median(range) 1.03 (0.79–1.27)
0.43
 
[55]
 
An important version of APTT is so-called clot waveform analysis that considers the entire optical density change curve, not only clot time. This assay is even included among the global assays [2-4]. In particular, two-phase curve in this assay is a sensitive and specific predictor of DIC (85% and 92%, respectively) [56]. This curve is explained by precipitation of C-reactive protein with VLDL upon addition of Са [57].
So, it seems that APTT is working in some cases of pro-coagulant changes in plasma, but these successes are mostly associated with changes in the concentrations of coagulation factor components, not with appearance of coagulation-activating circulating material. It is most likely that potent artificial clotting activation in APTT (and even stronger activation in INR) does not allow observation of small effects produced by circulating TF, fXIa, or microparticles. Protein C pathway does not function in APTT unless activated protein C is added, but even then thrombin generation using the same approach is more sensitive [58]. APTT does not include fibrinolysis in any way. Probably that is why APTT has no predictive value as a thrombosis risk marker following surgery [59,60], trauma [61], diabetes [55,62], cancer [63]. Data about pregnancy are contradictive [64,65]. The main hypercoagulation factor detected by APTT shortening is most likely increased concentration or activity of coagulation factor predecessors. For example, in the study [54], increase of the recurrence risk of VT disappeared after adjustment for factor VIII, IX and XI levels, and coagulation factor levels themselves had better predictive capacity of recurrence risk (RR = 2.38 for APTT ratio < 0.90, RR = 3.01; 3.06; 2.14 for increased levels of fVIII, dIX and fXI, respectively). Still, thrombophilic risk factors G1691A-factor V and G20210A-factor II did not differ significantly in groups with normal and shortened APTT [51].

Hypercoagulation and thrombin generation

Thrombin generation is one of the two best developed and tested global assays of hemostasis. Invented in its present form by the team of Coenraad Hemker of Maastricht University [66], the method uses a thrombin-sensitive chromogenic or, recently, fluorogenic substrate. From the velocity of its cleavage, thrombin concentration as a function of time is obtained and used for diagnostic purposes; it usually has a characteristic bell-shape. Such parameters as endogenous thrombin potential (ETP, area under the thrombin generation curve) are among the most widely used, and their correlation with clinical phenotype is well established. Interestingly, most of the thrombin generation curve is observed after clot formation, and its meaning is still a subject of debate [67].
There are presently numerous modifications of thrombin generation including several commercially available versions. Typically, the assay is performed in platelet free plasma supplemented with phospholipids; use of platelet-rich plasma is also possible. Triggering is done by picomolar TF concentration, although other stimuli can be used. Thrombin generation experiments can be done with TM, protein C-activating enzymes or simply activated protein C to better highlight the protein C pathway.
Tripodi et al. reported that patients with increased thrombin generation in the presence of TM have higher risk of recurrent venous thromboembolism. Those with ETP > 960 nM · min or thrombin peak >193 nM had hazard ratios (HR) for recurrent VTE of 3.41 or 4.57 as compared with those with an ETP <563 nM · min or peak <115 nm. Patients with lag-time <14.5 min had HR of 3.19 as compared with those with lag-time >20.8 min [68]. The same was reported by Besser et al.: after adjustment for D-dimer, thrombophilia, sex, and whether or not the first event was unprovoked, a high ETP remained a significant predictor of recurrence, HR 2.6 [69]. In a similar study of Hron et al., patients without recurrent VTE had lower thrombin generation than patients with recurrence (mean [SD], 349.2 [108.0] nM vs 419.5 [110.5] nM, respectively; P < .001). Compared with patients who had thrombin generation lower than 400 nM, the relative risk (RR) of recurrence was 2.4 [70]. Interestingly, van Hylckama Vlieg et al. did not find any predictive value for thrombosis risk though this might be due to a different experimental design [71]. Chaireti et al. found, paradoxically, that ETP immediately after thrombosis is lower in the group of thrombosis recurrence. If blood was collected 1-2 months after cancellation of anticoagulants, their ETP was insignificantly higher [72].
Increased ETP in platelet-rich plasma was reported for patients after ischemic stroke [73]. In PPP, increased thrombin peak predicted stroke for women and did not correlated with stroke in men (hazard ratio 1.04 for men, 1.7 for women) [74]. ETP is increased in almost any thrombophilia including G20210A mutation [75], AT deficiency [76], factor V Leiden [77] and protein S deficiency [78] (if experiments are with thrombomodulin), upon oral contraceptive use [79], in cancer [80]. ETP is increased in pregnancy [81,82], but seems to reach a plateau in the first trimester [83], while D-dimer, F1 + 2 and TAT increased, and there was no correlation between parameters of ETP assay and markers of in vivo thrombin generation. Lack of this correlation was confirmed in [80]. Patients with diabetes had significantly higher thrombin peak [55,62], probably because of increased level of factors II, V, VII, VIII, and X and decreased protein C [62].
Thrombin peak was reported to correlate with microparticle count, in particular when thrombin generation is performed without adding external activators and phospholipids [55]. Ollivier et al. found that lag time in recalcified plasma is sensitive to TF and does not affect the peak, while peak is sensitive to phospholipids. Distinct contributions of these two factors in cancer patients’ plasmas were differentiated in [84]. Lipopolysaccharides reliably decreased lag time [85].
It appears that thrombin generation is sensitive to various hypercoagulation factors depending on the design: to levels of factors II, V, Fg, AT at high TF (13.6рМ); to fXII, Fg, AT, free TFPI at low TF (1pM) [86], as well as to fVIII and fIX [87]; to protein C pathway defects upon addition of thrombomodulin or protein C activator [88]; to circulating TF when performed without activators; to lipids when performed without externally added lipids. Decrease of activation level increases overall sensitivity but increases deviation. Difference in the mean parameter values for patients with and without thrombosis is usually significant, but SDs usually overlap and it is complicated to transform such result into a clinical recommendation (Table 3). Although thrombin generation test standardization is presently under development [2] its lack restricts the method application.
Table 3
Examples of Trombin generation response to different procoagulant states
Procoagulant state
Number of patients in study group
TG trigger and additional substances
Data range in control group, mean ± SD unless otherwise indicated
Data range in group with hypercoagulation, mean ± SD unless otherwise indicated
Significance
Predictive value
Reference
Comments
Recurrence after first unprovoked VTE
254 – with a first VTE, 34 - with recurrence
1 pM TF 1 uM PL
ETP, nM∙min 1502 ± 446
ETP, nM∙min 1361 ± 499
0.122
1 tertile compared to the 3 HR = 2.54
[68]
Prospective study. Analysis was performed 2-3 months after completion of anticoagulant therapy.
IIa max, nM 232 ± 82
IIa max, nM 187 ± 89
0.005
HR = 3.09
Tlag, min 12 ± 6
Tlag, min 13 ± 5
0.319
HR = 2.29
 
1 pM TF 1 uM PL 4 nM TM
ETP, nM∙min 986 ± 422
ETP, nM∙min 763 ± 468
0.009
HR = 3.35
[68]
 
IIa max, nM 201 ± 75
IIa max, nM 148 ± 88
<0.001
HR = 4.49
Tlag, min 17 ± 7
Tlag, min 19 ± 10
0.174
HR = 2.39
Unprovoked recurrence after first VTE
188 with a first VTE, 29 – with recurrence
5 pM TF 4 uM PL
   
ETP > 50th percentile HR = 2.9
[69]
Prospective study. Analysis was performed 2-3 months after completion of anticoagulant therapy.
 
5 pM TF 4 uM PL 8nM TM
   
No significant predictive value
[69]
 
Recurrence after first unprovoked VTE
914 with a first VTE, 100 – with recurrence
72 pM TF 3.2 uM PL
IIa max, nM 349 ± 108
IIa max, nM 419 ± 110
<0.001
IIa max >400 nM RR = 2.5
[70]
Prospective study. Analysis was performed after completion of anticoagulant therapy.
First and recurrent VT
187 with a first unprovoked VT 404 controls
1/6 deluted plasma 2.5 pM TF 4 uM PL 1.2 nM TM
Mean ETP(95% CI), nM∙min 1641 (1607 -1676)
Mean ETP(95% CI), nM∙min 1695(1639–1750)
 
ETP > 90th percentile measured in control subjects DVT HR = 1.7
[71]
Analysis was performed 3 months after completion of anticoagulant therapy.
173 with a first provoked VT 404 controls
 
Mean ETP(95% CI), nM∙min 1641 (1607 -1676)
Mean ETP(95% CI), nM∙min 1649(1595-1703)
  
[71]
 
59 recurrent VTE
    
HR of recurrence 1.1
[71]
 
Recurrence after first unprovoked VTE
105 with a first VTE, 40 – with recurrence
5 pM TF 4 uM PL
ETP, nM∙min 1671 ± 514
ETP, nM∙min 1491 ± 536
0.111
 
[72]
Prospective study. Analysis was performed upon diagnosis of VTE
IIa max, nM 302 ± 91
IIa max, nM 261 ± 125
0.058
Tlag, min 7.2 ± 2.2
Tlag, min 8.7 ± 5
<0.001
Acute Ischemic Stroke (men)
42 patients 408 controls
5 pM TF 4 uM PL
geometric mean and interquartile range ETP, nM∙min 1755 (1620 - 1940)
geometric mean and interquartile range ETP, nM∙min 1720 (1572 - 1978)
 
HR = 0.88/sd
[74]
Prospective study.
IIa max, nM 327.0 (304.9 - 357.8)
IIa max, nM 330.2 (301.8 - 361.4)
 
HR = 1.04/sd
Acute Ischemic Stroke (women)
45 patients 666 controls
5 pM TF 4 uM PL
ETP, nM∙min 1755 (1604 - 1940)
ETP, nM∙min 1863 (1636 -1998)
 
HR = 1.55/sd
[74]
Prospective study
IIa max, nM 333.6 (311.0 - 372.4)
IIa max, nM 357.8 (320.5 - 391.5)
 
HR = 1.71/sd
Coronary Heart Disease events
186 patients 1000 controls
5 pM TF 4 uM PL
ETP, nM∙min 1765 (1620 - 1940)
ETP, nM∙min 1772 (1604- 1939
 
HR = 1.09/sd
[74]
Prospective study
IIa max, nM 333.0 (308.0 - 365.0)
IIa max, nM 330.3 (301.9- 357.8)
 
HR = 1.02/sd IIa max
Prothrombin G20210A mutation
148 heterozigote, 111 - controls
6.8 pM TF 30 uM PL
median and interquartile range ETP, nM∙min 1053 (946–1171)
median and interquartile range ETP, nM∙min 1358 (1190–1492)
the carriers as opposed to the non-carriers <0.001
 
[75]
 
IIa max, nM 292 (267–330)
IIa max, nM 349 (307–385)
<0.001
Tlag, min 2.54 (2.46–2.84)
Tlag, min 2.74 (2.46–3.04)
0.268
3 homozigote
 
ETP, nM∙min 1661 (1451–1976)
  
[75]
 
IIa max, nM 466 (446–470)
Tlag, min 3.06 (2.14–5.08)
AT III-inherited deficiency
9 - controls 18 Type I-IIRS/PE
5 pM TF 4 uM PL
ETP, nM∙min 2200 ± 320
ETP, nM∙min 3366 ± 668
Only Type I-IIRS/PE end controls ETP differs significantlly
 
[76]
 
IIa max, nM 377.3 ± 49.1
IIa max, nM 493.4 ± 75.0
17 -IIHBS heterozygote
 
ETP, nM∙min 2142 ± 464
IIa max, nM 427.2 ± 98.3
8 - Cambridge II heterozygote
 
ETP, nM∙min 2211 ± 268
IIa max, nM 391.4 ± 46.8
VTE in cancer patients
1033 cancer patients 77 VTE cases
71.6 pM TF 3.2 uM PL
median (25th to 75th percentile) ETP, nM∙min 4386 (3804-4890)
median (25th to 75th percentile) ETP, nM∙min 4475 (4087-4915)
0.197
IIa max > 611 nM (75th percentile) HR = 2.1
[80]
Prospective study
IIa max, nM 499 (360-603)
IIa max, nM 556 (432-677)
0.014
Type 2 diabetes mellitus
52 patients, 60 controls
1 pM TF 1 uM PL
Median (range) ETP, nM∙min 1844 (1,317–2592)
Median (range) ETP, nM∙min 1835 (1213–2656)
0.96
 
[55]
 
IIa max, nM 264 (97–432)
IIa max, nM 303 (207–434)
<0.001
Tlag, min 7.8 (4.7–18.4)
Tlag, min 5.9 (4.5–11.5)
<0.001
1 pM TF 1 uM PL 4 nM TM
ETP, nM∙min 1301 (535–2381)
ETP, nM∙min 1497 (1061–2418)
0.003
 
[55]
 
IIa max, nM 256 (79–433)
IIa max, nM 297 (216–427)
0.001
Tlag, min 10.4 (6.3–25.8)
Tlag, min 7.8 (5.6–13.6)
<0.001
43 patients, 60 controls
Ca only
ETP, nM∙min 1678 (539–2231)
ETP, nM∙min 1781 (288–2598)
0.05
 
[55]
 
IIa max, nM 151 (41–289)
IIa max, nM 202 (128–350)
<0.001
Tlag, min 12.6 (7.0–29.5)
Tlag, min 10.8 (7.2–16.1)
<0.001
Diabetes mellitus
89 patients
49 controls
5 pM TF 4 uM PL
ETP, nM∙min 1566.4 ± 240.7
ETP, nM∙min 1876.5 ± 390.0
<0.001
 
[62]
 
IIa max, nM 252.8 ± 44.6
IIa max, nM 308.9 ± 39.5
<0.001
Tlag, min 4.15 ± 0.74
Tlag, min 3.59 ± 0.62
<0.001
Normal pregnancy
19 health pregnant women 
10 controls
5 pM TF 20 uM PL 0.1 mg/ml CTI
ETP, nM∙min 1553 ± 567
pre-pregnancy ETP, nM∙min 1162 ± 446
Significant difference between pre-pregnancy and early/late pregnancy P < 0.001
 
[82]
 
IIa max, nM 81 ± 41
Early
ETP, nM∙min 2157 ± 466
IIa max, nM 159 ± 100
IIa max, nM 219 ± 117
Late ETP, nM∙min 2410 ± 543
IIa max, nM 336 ± 178
Normal pregnancy
1st Trimester (n = 36)
5 pM TF 4 uM PL
TG on normal pooled plasma was significantly lower than TG on pregnant women. The exact parameter’s values weren’t shown
ETP, nM∙min 2123 ± 335
No significant differences between trimesters
 
[83]
 
IIa max, nM 366 ± 43
2nd Trimester (n = 42)
ETP, nM∙min 2067 ± 326
IIa max, nM 374 ± 42
3rd Trimester (n = 23)
ETP, nM∙min 1915 ± 261
IIa max, nM 336 ± 49
Fibrinolysis and use of whole blood are currently beyond the available versions of this method, although some preliminary on thrombin generation in whole blood appeared [89]. There are no clinical data for thrombotic states for this version yet.

Evaluation of thrombosis risk with TEG/ROTEM

The most direct way to characterize clot formation is by rheometry, which has additional advantage of being independent of optical phenomena and easily applied in whole blood. There are numerous rheological approaches, and the best studied of them is thrombelastography. It is the most ancient global assay of hemostasis, where clot formation and platelet aggregation are evaluated simultaneously using forced oscillations rheometry.
Thrombelastography (TEG or ROTEM) has found a wide application for patients undergoing surgery as an alternative to APTT and INR that are not sensitive to hypercoagulation in this state [59,90]. A paper by Yue Dai et al. carefully examines reports between 1980 and 2008 about possibility to predict thrombosis using TEG, and majority of them answered positively. However, sensitivity and specificity varied between 0%-100% and 62%-92% respectively, with odds ratio reported between 1.5 and 27.7 [91] thus preventing meta-analysis. Later reports confirmed predictive value of maximal amplitude (MA) and clot firmness G (G = 5000 MA/100 – MA) as independent indicators of recurrent ischemic stroke after surgery (OR = 1.192, p = 0.022) [92]; the same was obtained for other thrombotic complications Similar data were obtained for ROTEM [90]. MA is believed to be mostly dependent on platelet function and fibrinogen concentration [93]; this might explain why it does not correlate with APTT and INR [92].
TEG revealed hypercoagulation in patients with prostate cancer, in particular in the group with metastases, in agreement with the increase of TF-expressing microparticles. Thrombotic complications arose in 7 out of 22 patients with increased TEG, while APTT and INR were normal [63]. TEG was able to detect hypercoagulation in patients with breast and colorectal cancer [94], gastrointestinal system tumors, respiratory system tumors, and miscellaneous tumors [95], after DVT [96], but not after cerebral venous thrombosis [97]. TEG is increased only in 57% patients with thrombophilia [98], this lack of sensitivity is confirmed in [97,99]. TEG reliably detect hypercoagulation in pregnancy that increases over the whole course [100-102] by parameters r, K, alfa, MA.
Like thrombin generation, thrombelastography is established to detect hypercoagulation, and there is evidence of both its shift in patient groups with known thrombotic risks and in patient groups with clinically occurring thrombosis. The pattern of sensitivity differs from that of thrombin generation: e.g., TEG is better in pregnancy but worse in thrombophilia. Still, wider use of this method suffers from the same shortcomings: deviations between donors are even greater that in thrombin generation resulting in poor difference between risks (Table 4), and there is lack of standardization.
Table 4
Examples of TEG response to different procoagulant states
Procoagulant state
Number of patients in study group
TEG version
Data range in control group,
mean ± SD unless otherwise indicated
Data range in group with hypercoagulation, mean ± SD unless otherwise indicated
Significance
Predictive value
Reference
Comments
Patients with acute ischemic stroke
93-Unfavorable outcome evaluatewd by modified Rankin Scale within a year 91-Favorable outcome
Citrate plasma was mixed with kaolin, and loaded in a heparinise-coated cup
means ± SE MA, mm 63.2 ± 0.5
means ± SE MA, mm 66.1 ± 0.6
<0.001
Prediction of unfavorable outcome At higher tertile of MA OR = 1.192
[92]
Prospective study.
Postoperative Thrombotic Complications
240 patients undergoing a wide variety of surgical procedure s, 10 thrombotic complications
celite-activated TEG on native blood samples within 4 min of collection
MA 66 ± 9
MA 71 ± 9
  
[103]
Prospective study. Thromboelastography was performed immediately after surgery.
6 myocardial infarction
 
MA 66 ± 9
MA 74 ± 5
 
OR = 1.16
Postoperative Thrombotic Complications
152 critically ill patients in the surgical intensive care unit 16 thrombotic complications
native blood, rTEG(activation with kaolin, human recombinant TF, phospholipids)
   
G > 12.4 dynes/cm OR = 1.25
[104]
 
Normal pregnancy
65/65
Recalcified citrate plasma
R, min 7.8 ± 2.5
R, min 6.1 ± 1.8
<0.001
 
[102]
 
K, min 2.7 ± 2.3
K, min 1.4 ± 0.5
Alfa, deg 57.7 ± 11.6
Alfa, deg 70.6 ± 6.5
MA, mm 61 ± 5.9
MA, mm 71 ± 3.8
Ly 30, % 0.8 ± 1.7
Ly 30, % 0.3 ± 0.7

Novel assays

There are several innovative global assays that are not used widely yet but may be promising as they include some really important aspects. Some of them are versions of the existing ones (e.g. there are numerous rheometric approaches beyond TEG [105]), while others use completely innovative principles. Below we discuss the methods that have been tested with regard to the pro-thrombotic sensitivity.

Thrombin-and-plasmin generation

There are several versions of the method to detect thrombin and plasmin at once [106-108]. Increased coagulation and impaired fibrinolysis are detected by means of overall hemostasis potential in patients with acquired arterial thrombotic events and vasculopathies, such as diabetic patients with microvascular complications, 15 patients with preeclampsia, 16 and elderly female patients with coronary heart disease [106]. Although the data are very scarce, this method is interesting as the only known alternative to TEG with regard to fibrinolysis evaluation.

Thrombodynamics

A novel strategy of blood coagulation testing is proposed in the thrombodynamics assay that has been developed and used as a research tool for almost two decades and became commercially available for clinical labs in 2012. The central idea of the method is monitoring spatial fibrin formation initiated by immobilized tissue factor in plasma by videomicroscopy [109], so that clot is initially formed on the activator and then propagates into plasma. A version of the assay exists that can determine thrombin formation as a function of time and space in parallel with fibrin [110].
The idea behind this is to take into account spatial heterogeneity of blood coagulation, in other words, the fact that clotting initiation and propagation occurs in spatially separated regions [111]. In agreement with the wound clotting in vivo, tissue factor is located on the surface, and clot propagates because of coagulation factor activation and diffusion [112]. Importantly, separation of the activation and propagation phases makes the assay particularly sensitive to the presence of coagulation activators in plasma such as circulating tissue factor [112] or factor XIa [43]. Spatial clot formation velocity indicates overall procoagulant potential, while formation of activator-independent spontaneous clotting centers may indicate presence of microparticles and long-lived coagulation factors [43]. Pre-analytical standardization for this assay has also recently become available [113].
These biochemical findings have been confirmed by several preliminary studies. Hypercoagulation detected by thrombodynamics in patients with sepsis was confirmed by subsequent increase of D-dimers and occasional thrombosis [114]. Spontaneous clotting and increase spatial clot growth velocity were observed in patients with well-known thrombotic risks suffering from lymphomas, lymphogranulomatosis, thrombophilia, hemolytic anemia, acute leukemia, cardiac infarction [43]; the same was observed in a detailed study of multiple myeloma [115]. A case study demonstrated ability of thrombodynamics to detect hypercoagulation in beta-thalassemia [116]; portal vein thrombosis occurred after several weeks of increased clot growth velocity. In some of these papers, comparison was done with thrombin generation and thrombelastography, which did not show hypercoagulation changes in most cases.
To summarize, thrombodynamics assay shows significant promise as a tool to detect hypercoagulation and evaluate thrombotic risk, but additional clinical research is needed to establish a reliable relationship between assays indicators and thrombosis risks.

Flow perfusion chambers

Formation of platelets-and-fibrin thrombi in flow chambers observed by microscopy is potentially an “ultimate” global assay that is able to evaluate both platelet functions (including adhesion, aggregation, and procoagulant activity) and blood coagulation. Such microfluidic devices are being actively developed and used for various applications (see recent review in [116]). Review of this rapidly developing field is beyond the scope of the present paper. However, it should be noted that there are reports on the ability of flow perfusion chambers to detect hypercoagulation changes in blood [117-119]. However, there are few clinical studies and standardization status of these chambers is very poor [120]. Although theroretical consideration suggest significant potential of flow chambers, they have a long way to go in order to become a clinical tool.

Conclusions

The first conclusion of the present analysis is that the claim of the global assays that they can detect functional hypercoagulation is valid, to a significant degree. Compared with INR and APTT, sensitivity of the new global assays to hypercoagulation is definitely higher and encompasses a wider range of disorders and hypercoagulation causes. It is likely that there are two reasons behind this. First, these novel assays use smaller concentrations of activators, which do not obscure the effect of circulating pro-coagulant material (or, in some cases, activation and propagation phases are spatially separated). Second, the parameters provided by new global assays might be more sensitive than just time of clot formation, and involvement of all major reactions makes the assays sensitive to other pro-coagulant changes.
However, there are two major issues that complicate use of global assays for the evaluation of thrombotic risks.
The most important concern is that conclusion about sensitivity of the assays is usually reached with large patient cohorts only, standard deviations are large, and the differences of mean assay parameters between groups are significant mostly because of large statistics (Tables 2, 3 and 4). In other words, if we attempt to define boundaries and select patient groups with different risks based on the assay parameters, the overall difference of thrombotic risk between groups is not usually large. It is questionable whether this difference is sufficient to affect clinical decisions. Some of the novel assays show promise of sensitivity increase, but their clinical utility also remains to be tested directly.
Another concern is lack of standardization. There are numerous versions for each assay, and clinical investigations often use different approaches, and the assay sensitivity strongly depends on the protocol used. Therefore, the results from different papers cited in this review might be difficult to interpret and to reproduce. The current attempts at standardization for some of the better established global assays such as thrombin generation [121-123]) make us hope that this might be resolved in the foreseeable future.

Acknowledgements

The study was supported by the Russian Academy of Sciences Presidium Basic Research Programs ‘Basic Research for Development of Biomedical Technologies’, ‘Molecular and Cellular Biology’, ‘Basic Science for Medicine’ and ‘Integrative Physiology’, and by the Russian Foundation for Basic Research grants 14-04-00670, 13-04-00401 and 12-04-00438. E.N.L. gratefully acknowledges support of her work on contact activation from Russian Science Foundation grant 14-14-00195.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Competing interest

FA is an employee and a founder of HemaCore LLC that holds several patents on the use of spatial clot growth dynamics for blood clotting diagnostics, and develops the spatial clot growth assay under the trade name of Thrombodynamics.

Authors’ contributions

EL collected and analyzed literature data, wrote the paper. FI wrote the paper, revised it critically, have given final approval of the version to be published. All authors read and approved the final manuscript.
Literatur
1.
Zurück zum Zitat Sinauridze EI, Panteleev MA, Ataullakhanov FI. Anticoagulant therapy: basic principles, classic approaches and recent developments. Blood Coagul Fibrinolysis. 2012;23:482–93.PubMed Sinauridze EI, Panteleev MA, Ataullakhanov FI. Anticoagulant therapy: basic principles, classic approaches and recent developments. Blood Coagul Fibrinolysis. 2012;23:482–93.PubMed
2.
Zurück zum Zitat Brummel-Ziedins KE, Wolberg AS. Global assays of hemostasis. Curr Opin Hematol. 2014;21:395–403.PubMed Brummel-Ziedins KE, Wolberg AS. Global assays of hemostasis. Curr Opin Hematol. 2014;21:395–403.PubMed
3.
Zurück zum Zitat van Geffen M, van Heerde WL. Global haemostasis assays, from bench to bedside. Thromb Res. 2012;129:681–7.PubMed van Geffen M, van Heerde WL. Global haemostasis assays, from bench to bedside. Thromb Res. 2012;129:681–7.PubMed
4.
Zurück zum Zitat Dargaud Y, Sorensen B, Shima M, Hayward C, Srivastava A, Negrier C. Global haemostasis and point of care testing. Haemophilia. 2012;18 Suppl 4:81–8.PubMed Dargaud Y, Sorensen B, Shima M, Hayward C, Srivastava A, Negrier C. Global haemostasis and point of care testing. Haemophilia. 2012;18 Suppl 4:81–8.PubMed
5.
Zurück zum Zitat Lopez JA, Chen J. Pathophysiology of venous thrombosis. Thromb Res. 2009;123 Suppl 4:S30–4.PubMed Lopez JA, Chen J. Pathophysiology of venous thrombosis. Thromb Res. 2009;123 Suppl 4:S30–4.PubMed
6.
Zurück zum Zitat Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program 2004(1):439-456. Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program 2004(1):439-456.
7.
Zurück zum Zitat Friedman MH, Brinkman AM, Qin JJ, Seed WA. Relation between coronary artery geometry and the distribution of early sudanophilic lesions. Atherosclerosis. 1993;98:193–9.PubMed Friedman MH, Brinkman AM, Qin JJ, Seed WA. Relation between coronary artery geometry and the distribution of early sudanophilic lesions. Atherosclerosis. 1993;98:193–9.PubMed
8.
9.
Zurück zum Zitat von Bruhl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209:819–35. von Bruhl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209:819–35.
10.
Zurück zum Zitat Lawson CA, Yan SD, Yan SF, Liao H, Zhou YS, Sobel J, et al. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest. 1997;99:1729–38.PubMedCentralPubMed Lawson CA, Yan SD, Yan SF, Liao H, Zhou YS, Sobel J, et al. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest. 1997;99:1729–38.PubMedCentralPubMed
11.
Zurück zum Zitat Lacroix R, Dubois C, Leroyer AS, Sabatier F, Dignat-George F. Revisited role of microparticles in arterial and venous thrombosis. J Thromb Haemost. 2013;11 Suppl 1:24–35.PubMed Lacroix R, Dubois C, Leroyer AS, Sabatier F, Dignat-George F. Revisited role of microparticles in arterial and venous thrombosis. J Thromb Haemost. 2013;11 Suppl 1:24–35.PubMed
12.
Zurück zum Zitat Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renne T, ten Cate H, Spronk HM. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost. 2012;10:1355–62. Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renne T, ten Cate H, Spronk HM. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost. 2012;10:1355–62.
13.
Zurück zum Zitat Shibeko AM, Lobanova ES, Panteleev MA, Ataullakhanov FI. Blood flow controls coagulation onset via the positive feedback of factor VII activation by factor Xa. BMC Syst Biol. 2010;4:5.PubMedCentralPubMed Shibeko AM, Lobanova ES, Panteleev MA, Ataullakhanov FI. Blood flow controls coagulation onset via the positive feedback of factor VII activation by factor Xa. BMC Syst Biol. 2010;4:5.PubMedCentralPubMed
14.
Zurück zum Zitat Tokarev AA, Butylin AA, Ataullakhanov FI. Platelet adhesion from shear blood flow is controlled by near-wall rebounding collisions with erythrocytes. Biophys J. 2011;100:799–808.PubMedCentralPubMed Tokarev AA, Butylin AA, Ataullakhanov FI. Platelet adhesion from shear blood flow is controlled by near-wall rebounding collisions with erythrocytes. Biophys J. 2011;100:799–808.PubMedCentralPubMed
15.
Zurück zum Zitat Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–94.PubMed Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–94.PubMed
16.
Zurück zum Zitat Sonneveld MA, de Maat MP, Leebeek FW. Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev. 2014;28:167–78.PubMed Sonneveld MA, de Maat MP, Leebeek FW. Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev. 2014;28:167–78.PubMed
17.
Zurück zum Zitat Kubisz P, Ruiz-Arguelles GJ, Stasko J, Holly P, Ruiz-Delgado GJ. Sticky platelet syndrome: history and future perspectives. Semin Thromb Hemost. 2014;40:526–34.PubMed Kubisz P, Ruiz-Arguelles GJ, Stasko J, Holly P, Ruiz-Delgado GJ. Sticky platelet syndrome: history and future perspectives. Semin Thromb Hemost. 2014;40:526–34.PubMed
18.
Zurück zum Zitat Undas A, Slowik A, Gissel M, Mann KG, Butenas S. Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events. Thromb Res. 2011;128:e62–6.PubMedCentralPubMed Undas A, Slowik A, Gissel M, Mann KG, Butenas S. Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events. Thromb Res. 2011;128:e62–6.PubMedCentralPubMed
19.
Zurück zum Zitat Zabczyk M, Butenas S, Plicner D, Fijorek K, Sadowski J, Undas A. Factors associated with the presence of circulating active tissue factor and activated factor XI in stable angina patients. Blood Coagul Fibrinolysis. 2012;23:189–94.PubMed Zabczyk M, Butenas S, Plicner D, Fijorek K, Sadowski J, Undas A. Factors associated with the presence of circulating active tissue factor and activated factor XI in stable angina patients. Blood Coagul Fibrinolysis. 2012;23:189–94.PubMed
20.
Zurück zum Zitat Zabczyk M, Butenas S, Palka I, Nessler J, Undas A. Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy. Pol Arch Med Wewn. 2010;120:334–40.PubMedCentralPubMed Zabczyk M, Butenas S, Palka I, Nessler J, Undas A. Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy. Pol Arch Med Wewn. 2010;120:334–40.PubMedCentralPubMed
21.
Zurück zum Zitat Weitz JI. Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. Thromb Haemost. 2014;112(5):924–31.PubMed Weitz JI. Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. Thromb Haemost. 2014;112(5):924–31.PubMed
22.
Zurück zum Zitat Kwaan HC. Microvascular thrombosis: a serious and deadly pathologic process in multiple diseases. Semin Thromb Hemost. 2011;37:961–78.PubMed Kwaan HC. Microvascular thrombosis: a serious and deadly pathologic process in multiple diseases. Semin Thromb Hemost. 2011;37:961–78.PubMed
23.
Zurück zum Zitat Bellido-Martin L, Chen V, Jasuja R, Furie B, Furie BC. Imaging fibrin formation and platelet and endothelial cell activation in vivo. Thromb Haemost. 2011;105:776–82.PubMed Bellido-Martin L, Chen V, Jasuja R, Furie B, Furie BC. Imaging fibrin formation and platelet and endothelial cell activation in vivo. Thromb Haemost. 2011;105:776–82.PubMed
24.
Zurück zum Zitat Pfeiler S, Massberg S, Engelmann B. Biological basis and pathological relevance of microvascular thrombosis. Thromb Res. 2014;133 Suppl 1:S35–7.PubMed Pfeiler S, Massberg S, Engelmann B. Biological basis and pathological relevance of microvascular thrombosis. Thromb Res. 2014;133 Suppl 1:S35–7.PubMed
25.
Zurück zum Zitat Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost. 2013;39:559–66.PubMed Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost. 2013;39:559–66.PubMed
26.
Zurück zum Zitat Langer F, Bokemeyer C. Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor. Hamostaseologie. 2012;32:95–104.PubMed Langer F, Bokemeyer C. Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor. Hamostaseologie. 2012;32:95–104.PubMed
27.
Zurück zum Zitat Barrabes JA, Inserte J, Agullo L, Alonso A, Mirabet M, Garcia-Dorado D. Microvascular thrombosis: an exciting but elusive therapeutic target in reperfused acute myocardial infarction. Cardiovasc Hematol Disord Drug Targets. 2010;10:273–83.PubMed Barrabes JA, Inserte J, Agullo L, Alonso A, Mirabet M, Garcia-Dorado D. Microvascular thrombosis: an exciting but elusive therapeutic target in reperfused acute myocardial infarction. Cardiovasc Hematol Disord Drug Targets. 2010;10:273–83.PubMed
28.
Zurück zum Zitat Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011;17:5858–66.PubMedCentralPubMed Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011;17:5858–66.PubMedCentralPubMed
29.
Zurück zum Zitat Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med. 2010;38:S35–42.PubMed Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med. 2010;38:S35–42.PubMed
30.
Zurück zum Zitat Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res. 2012;129:290–5.PubMed Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res. 2012;129:290–5.PubMed
31.
Zurück zum Zitat Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105:1734–41.PubMed Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105:1734–41.PubMed
32.
Zurück zum Zitat Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013;122:1873–80.PubMedCentralPubMed Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013;122:1873–80.PubMedCentralPubMed
33.
Zurück zum Zitat Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost. 2007;5:520–7.PubMed Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost. 2007;5:520–7.PubMed
34.
Zurück zum Zitat Levi M. Cancer and thrombosis. Clin Adv Hematol Oncol. 2003;1:668–71.PubMed Levi M. Cancer and thrombosis. Clin Adv Hematol Oncol. 2003;1:668–71.PubMed
35.
Zurück zum Zitat Demers M, Wagner DD. Neutrophil extracellular traps: A new link to cancer-associated thrombosis and potential implications for tumor progression. Oncoimmunology. 2013;2:e22946.PubMedCentralPubMed Demers M, Wagner DD. Neutrophil extracellular traps: A new link to cancer-associated thrombosis and potential implications for tumor progression. Oncoimmunology. 2013;2:e22946.PubMedCentralPubMed
36.
Zurück zum Zitat Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 2003;112:853–62.PubMedCentralPubMed Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 2003;112:853–62.PubMedCentralPubMed
37.
Zurück zum Zitat Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol. 2003;16:153–68.PubMed Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol. 2003;16:153–68.PubMed
38.
Zurück zum Zitat Medcalf RL, Stasinopoulos SJ. The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. Febs J. 2005;272:4858–67.PubMed Medcalf RL, Stasinopoulos SJ. The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. Febs J. 2005;272:4858–67.PubMed
39.
Zurück zum Zitat Alijotas-Reig J, Palacio-Garcia C, Llurba E, Vilardell-Tarres M. Cell-derived microparticles and vascular pregnancy complications: a systematic and comprehensive review. Fertil Steril. 2013;99:441–9.PubMed Alijotas-Reig J, Palacio-Garcia C, Llurba E, Vilardell-Tarres M. Cell-derived microparticles and vascular pregnancy complications: a systematic and comprehensive review. Fertil Steril. 2013;99:441–9.PubMed
40.
Zurück zum Zitat Patil R, Ghosh K, Satoskar P, Shetty S. Elevated procoagulant endothelial and tissue factor expressing microparticles in women with recurrent pregnancy loss. PLoS One. 2013;8:e81407.PubMedCentralPubMed Patil R, Ghosh K, Satoskar P, Shetty S. Elevated procoagulant endothelial and tissue factor expressing microparticles in women with recurrent pregnancy loss. PLoS One. 2013;8:e81407.PubMedCentralPubMed
41.
Zurück zum Zitat Sandset PM. Mechanisms of hormonal therapy related thrombosis. Thromb Res. 2013;131 Suppl 1:S4–7.PubMed Sandset PM. Mechanisms of hormonal therapy related thrombosis. Thromb Res. 2013;131 Suppl 1:S4–7.PubMed
42.
Zurück zum Zitat Morel O, Jesel L, Abbas M, Morel N. Prothrombotic changes in diabetes mellitus. Semin Thromb Hemost. 2013;39:477–88.PubMed Morel O, Jesel L, Abbas M, Morel N. Prothrombotic changes in diabetes mellitus. Semin Thromb Hemost. 2013;39:477–88.PubMed
43.
Zurück zum Zitat Lipets E, Vlasova O, Urnova E, Margolin O, Soloveva A, Ostapushchenko O, et al. Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients. PLoS One. 2014;9:e87692.PubMedCentralPubMed Lipets E, Vlasova O, Urnova E, Margolin O, Soloveva A, Ostapushchenko O, et al. Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients. PLoS One. 2014;9:e87692.PubMedCentralPubMed
44.
Zurück zum Zitat Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–703.PubMed Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–703.PubMed
45.
Zurück zum Zitat Lindahl TL, Lundahl TH, Nilsson L, Andersson CA. APC-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee–a prospective study. Thromb Haemost. 1999;81:18–21.PubMed Lindahl TL, Lundahl TH, Nilsson L, Andersson CA. APC-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee–a prospective study. Thromb Haemost. 1999;81:18–21.PubMed
46.
Zurück zum Zitat Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504–8.PubMed Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504–8.PubMed
47.
Zurück zum Zitat Lijfering WM, Brouwer JL, Veeger NJ, Bank I, Coppens M, Middeldorp S, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood. 2009;113:5314–22.PubMed Lijfering WM, Brouwer JL, Veeger NJ, Bank I, Coppens M, Middeldorp S, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood. 2009;113:5314–22.PubMed
48.
Zurück zum Zitat Koster T, Rosendaal FR, Briet E, van der Meer FJ, Colly LP, Trienekens PH, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995;85:2756–61.PubMed Koster T, Rosendaal FR, Briet E, van der Meer FJ, Colly LP, Trienekens PH, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995;85:2756–61.PubMed
49.
Zurück zum Zitat Levy JH, Szlam F, Wolberg AS, Winkler A. Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. Clin Lab Med. 2014;34:453–77.PubMed Levy JH, Szlam F, Wolberg AS, Winkler A. Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. Clin Lab Med. 2014;34:453–77.PubMed
50.
Zurück zum Zitat Mina A, Favaloro EJ, Mohammed S, Koutts J. A laboratory evaluation into the short activated partial thromboplastin time. Blood Coagul Fibrinolysis. 2010;21:152–7.PubMed Mina A, Favaloro EJ, Mohammed S, Koutts J. A laboratory evaluation into the short activated partial thromboplastin time. Blood Coagul Fibrinolysis. 2010;21:152–7.PubMed
51.
Zurück zum Zitat Ten Boekel E, Bartels P. Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1 + 2, D-dimer and FVIII:C. Pathophysiol Haemost Thromb. 2002;32:137–42.PubMed Ten Boekel E, Bartels P. Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1 + 2, D-dimer and FVIII:C. Pathophysiol Haemost Thromb. 2002;32:137–42.PubMed
52.
Zurück zum Zitat Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci PM. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood. 2004;104:3631–4.PubMed Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci PM. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood. 2004;104:3631–4.PubMed
53.
Zurück zum Zitat Hron G, Eichinger S, Weltermann A, Quehenberger P, Halbmayer WM, Kyrle PA. Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J Thromb Haemost. 2006;4:752–6.PubMed Hron G, Eichinger S, Weltermann A, Quehenberger P, Halbmayer WM, Kyrle PA. Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J Thromb Haemost. 2006;4:752–6.PubMed
54.
Zurück zum Zitat Legnani C, Mattarozzi S, Cini M, Cosmi B, Favaretto E, Palareti G. Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. Br J Haematol. 2006;134:227–32.PubMed Legnani C, Mattarozzi S, Cini M, Cosmi B, Favaretto E, Palareti G. Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. Br J Haematol. 2006;134:227–32.PubMed
55.
Zurück zum Zitat Tripodi A, Branchi A, Chantarangkul V, Clerici M, Merati G, Artoni A, et al. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis. 2011;31:165–72.PubMed Tripodi A, Branchi A, Chantarangkul V, Clerici M, Merati G, Artoni A, et al. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis. 2011;31:165–72.PubMed
56.
Zurück zum Zitat Hussain N, Hodson D, Marcus R, Baglin T, Luddington R. The biphasic transmittance waveform: an early marker of sepsis in patients with neutropenia. Thromb Haemost. 2008;100:146–8.PubMed Hussain N, Hodson D, Marcus R, Baglin T, Luddington R. The biphasic transmittance waveform: an early marker of sepsis in patients with neutropenia. Thromb Haemost. 2008;100:146–8.PubMed
57.
Zurück zum Zitat Toh CH, Samis J, Downey C, Walker J, Becker L, Brufatto N, et al. Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood. 2002;100:2522–9.PubMed Toh CH, Samis J, Downey C, Walker J, Becker L, Brufatto N, et al. Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood. 2002;100:2522–9.PubMed
58.
Zurück zum Zitat Curvers J, Thomassen MC, Nicolaes GA, Van Oerle R, Hamulyak K, Hemker HC, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol. 1999;105:88–94.PubMed Curvers J, Thomassen MC, Nicolaes GA, Van Oerle R, Hamulyak K, Hemker HC, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol. 1999;105:88–94.PubMed
59.
Zurück zum Zitat Park MS, Martini WZ, Dubick MA, Salinas J, Butenas S, Kheirabadi BS, et al. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma. 2009;67:266–75. discussion 275-266.PubMedCentralPubMed Park MS, Martini WZ, Dubick MA, Salinas J, Butenas S, Kheirabadi BS, et al. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma. 2009;67:266–75. discussion 275-266.PubMedCentralPubMed
60.
Zurück zum Zitat Schreiber MA, Differding J, Thorborg P, Mayberry JC, Mullins RJ. Hypercoagulability is most prevalent early after injury and in female patients. J Trauma. 2005;58:475–80. discussion 480-471.PubMed Schreiber MA, Differding J, Thorborg P, Mayberry JC, Mullins RJ. Hypercoagulability is most prevalent early after injury and in female patients. J Trauma. 2005;58:475–80. discussion 480-471.PubMed
61.
Zurück zum Zitat Kaufmann CR, Dwyer KM, Crews JD, Dols SJ, Trask AL. Usefulness of thrombelastography in assessment of trauma patient coagulation. J Trauma. 1997;42:716–20. discussion 720-712.PubMed Kaufmann CR, Dwyer KM, Crews JD, Dols SJ, Trask AL. Usefulness of thrombelastography in assessment of trauma patient coagulation. J Trauma. 1997;42:716–20. discussion 720-712.PubMed
62.
Zurück zum Zitat Kim HK, Kim JE, Park SH, Kim YI, Nam-Goong IS, Kim ES. High coagulation factor levels and low protein C levels contribute to enhanced thrombin generation in patients with diabetes who do not have macrovascular complications. J Diabetes Complications. 2014;28:365–9.PubMed Kim HK, Kim JE, Park SH, Kim YI, Nam-Goong IS, Kim ES. High coagulation factor levels and low protein C levels contribute to enhanced thrombin generation in patients with diabetes who do not have macrovascular complications. J Diabetes Complications. 2014;28:365–9.PubMed
63.
Zurück zum Zitat Toukh M, Siemens DR, Black A, Robb S, Leveridge M, Graham CH, et al. Thromboelastography identifies hypercoagulability and predicts thromboembolic complications in patients with prostate cancer. Thromb Res. 2014;133:88–95.PubMed Toukh M, Siemens DR, Black A, Robb S, Leveridge M, Graham CH, et al. Thromboelastography identifies hypercoagulability and predicts thromboembolic complications in patients with prostate cancer. Thromb Res. 2014;133:88–95.PubMed
64.
Zurück zum Zitat Othman M, Falcon BJ, Kadir R. Global hemostasis in pregnancy: are we using thromboelastography to its full potential? Semin Thromb Hemost. 2010;36:738–46.PubMed Othman M, Falcon BJ, Kadir R. Global hemostasis in pregnancy: are we using thromboelastography to its full potential? Semin Thromb Hemost. 2010;36:738–46.PubMed
65.
Zurück zum Zitat Hammerova L, Chabada J, Drobny J, Batorova A. Longitudinal evaluation of markers of hemostasis in pregnancy. Bratisl Lek Listy. 2014;115:140–4.PubMed Hammerova L, Chabada J, Drobny J, Batorova A. Longitudinal evaluation of markers of hemostasis in pregnancy. Bratisl Lek Listy. 2014;115:140–4.PubMed
66.
Zurück zum Zitat Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost. 1993;70:617–24.PubMed Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost. 1993;70:617–24.PubMed
67.
Zurück zum Zitat Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1:1504–14.PubMed Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1:1504–14.PubMed
68.
Zurück zum Zitat Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost. 2008;6:1327–33.PubMed Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost. 2008;6:1327–33.PubMed
69.
Zurück zum Zitat Besser M, Baglin C, Luddington R, van Hylckama VA, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost. 2008;6:1720–5.PubMed Besser M, Baglin C, Luddington R, van Hylckama VA, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost. 2008;6:1720–5.PubMed
70.
Zurück zum Zitat Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. Jama. 2006;296:397–402.PubMed Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. Jama. 2006;296:397–402.PubMed
71.
Zurück zum Zitat van Hylckama VA, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol. 2007;138:769–74. van Hylckama VA, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol. 2007;138:769–74.
72.
Zurück zum Zitat Chaireti R, Jennersjo C, Lindahl TL. Is thrombin generation at the time of an acute thromboembolic episode a predictor of recurrence? The LInkoping Study on Thrombosis (LIST)–a 7-year follow-up. Thromb Res. 2013;131:135–9.PubMed Chaireti R, Jennersjo C, Lindahl TL. Is thrombin generation at the time of an acute thromboembolic episode a predictor of recurrence? The LInkoping Study on Thrombosis (LIST)–a 7-year follow-up. Thromb Res. 2013;131:135–9.PubMed
73.
Zurück zum Zitat Faber CG, Lodder J, Kessels F, Troost J. Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients. Pathophysiol Haemost Thromb. 2003;33:52–8.PubMed Faber CG, Lodder J, Kessels F, Troost J. Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients. Pathophysiol Haemost Thromb. 2003;33:52–8.PubMed
74.
Zurück zum Zitat Carcaillon L, Alhenc-Gelas M, Bejot Y, Spaft C, Ducimetiere P, Ritchie K, et al. Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly: the Three-City cohort study. Arterioscler Thromb Vasc Biol. 2011;31:1445–51.PubMed Carcaillon L, Alhenc-Gelas M, Bejot Y, Spaft C, Ducimetiere P, Ritchie K, et al. Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly: the Three-City cohort study. Arterioscler Thromb Vasc Biol. 2011;31:1445–51.PubMed
75.
Zurück zum Zitat Castoldi E, Simioni P, Tormene D, Thomassen MC, Spiezia L, Gavasso S, et al. Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. J Thromb Haemost. 2007;5:971–9.PubMed Castoldi E, Simioni P, Tormene D, Thomassen MC, Spiezia L, Gavasso S, et al. Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. J Thromb Haemost. 2007;5:971–9.PubMed
76.
Zurück zum Zitat Alhenc-Gelas M, Canonico M, Picard V. Influence of natural SERPINC1 mutations on ex vivo thrombin generation. J Thromb Haemost. 2010;8:845–8.PubMed Alhenc-Gelas M, Canonico M, Picard V. Influence of natural SERPINC1 mutations on ex vivo thrombin generation. J Thromb Haemost. 2010;8:845–8.PubMed
77.
Zurück zum Zitat Simioni P, Castoldi E, Lunghi B, Tormene D, Rosing J, Bernardi F. An underestimated combination of opposites resulting in enhanced thrombotic tendency. Blood. 2005;106:2363–5.PubMed Simioni P, Castoldi E, Lunghi B, Tormene D, Rosing J, Bernardi F. An underestimated combination of opposites resulting in enhanced thrombotic tendency. Blood. 2005;106:2363–5.PubMed
78.
Zurück zum Zitat Castoldi E, Maurissen LF, Tormene D, Spiezia L, Gavasso S, Radu C, et al. Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency. Haematologica. 2010;95:1563–71.PubMedCentralPubMed Castoldi E, Maurissen LF, Tormene D, Spiezia L, Gavasso S, Radu C, et al. Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency. Haematologica. 2010;95:1563–71.PubMedCentralPubMed
79.
Zurück zum Zitat Tchaikovski SN, van Vliet HA, Thomassen MC, Bertina RM, Rosendaal FR, Sandset PM, et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost. 2007;98:1350–6.PubMed Tchaikovski SN, van Vliet HA, Thomassen MC, Bertina RM, Rosendaal FR, Sandset PM, et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost. 2007;98:1350–6.PubMed
80.
Zurück zum Zitat Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2011;29:2099–103.PubMed Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2011;29:2099–103.PubMed
81.
Zurück zum Zitat Rosenkranz A, Hiden M, Leschnik B, Weiss EC, Schlembach D, Lang U, et al. Calibrated automated thrombin generation in normal uncomplicated pregnancy. Thromb Haemost. 2008;99:331–7.PubMed Rosenkranz A, Hiden M, Leschnik B, Weiss EC, Schlembach D, Lang U, et al. Calibrated automated thrombin generation in normal uncomplicated pregnancy. Thromb Haemost. 2008;99:331–7.PubMed
82.
Zurück zum Zitat McLean KC, Bernstein IM, Brummel-Ziedins KE. Tissue factor-dependent thrombin generation across pregnancy. Am J Obstet Gynecol. 2012;207(135):e131–6. McLean KC, Bernstein IM, Brummel-Ziedins KE. Tissue factor-dependent thrombin generation across pregnancy. Am J Obstet Gynecol. 2012;207(135):e131–6.
83.
Zurück zum Zitat Joly B, Barbay V, Borg JY, Le Cam-Duchez V. Comparison of markers of coagulation activation and thrombin generation test in uncomplicated pregnancies. Thromb Res. 2013;132:386–91.PubMed Joly B, Barbay V, Borg JY, Le Cam-Duchez V. Comparison of markers of coagulation activation and thrombin generation test in uncomplicated pregnancies. Thromb Res. 2013;132:386–91.PubMed
84.
Zurück zum Zitat Debaugnies F, Azerad MA, Noubouossie D, Rozen L, Hemker HC, Corazza F, et al. Evaluation of the procoagulant activity in the plasma of cancer patients using a thrombin generation assay. Thromb Res. 2010;126:531–5.PubMed Debaugnies F, Azerad MA, Noubouossie D, Rozen L, Hemker HC, Corazza F, et al. Evaluation of the procoagulant activity in the plasma of cancer patients using a thrombin generation assay. Thromb Res. 2010;126:531–5.PubMed
85.
Zurück zum Zitat Ollivier V, Wang J, Manly D, Machlus KR, Wolberg AS, Jandrot-Perrus M, et al. Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay. Thromb Res. 2010;125:90–6.PubMedCentralPubMed Ollivier V, Wang J, Manly D, Machlus KR, Wolberg AS, Jandrot-Perrus M, et al. Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay. Thromb Res. 2010;125:90–6.PubMedCentralPubMed
86.
Zurück zum Zitat Dielis AW, Castoldi E, Spronk HM, van Oerle R, Hamulyak K, Ten Cate H, et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost. 2008;6:125–31.PubMed Dielis AW, Castoldi E, Spronk HM, van Oerle R, Hamulyak K, Ten Cate H, et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost. 2008;6:125–31.PubMed
87.
Zurück zum Zitat van Veen JJ, Gatt A, Cooper PC, Kitchen S, Bowyer AE, Makris M. Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters. Blood Coagul Fibrinolysis. 2008;19:183–9.PubMed van Veen JJ, Gatt A, Cooper PC, Kitchen S, Bowyer AE, Makris M. Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters. Blood Coagul Fibrinolysis. 2008;19:183–9.PubMed
88.
Zurück zum Zitat Dargaud Y, Trzeciak MC, Bordet JC, Ninet J, Negrier C. Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost. 2006;96:562–7.PubMed Dargaud Y, Trzeciak MC, Bordet JC, Ninet J, Negrier C. Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost. 2006;96:562–7.PubMed
89.
Zurück zum Zitat Ninivaggi M, Apitz-Castro R, Dargaud Y, de Laat B, Hemker HC, Lindhout T. Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. Clin Chem. 2012;58:1252–9.PubMed Ninivaggi M, Apitz-Castro R, Dargaud Y, de Laat B, Hemker HC, Lindhout T. Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. Clin Chem. 2012;58:1252–9.PubMed
90.
Zurück zum Zitat Hincker A, Feit J, Sladen RN, Wagener G. Rotational thromboelastometry predicts thromboembolic complications after major non-cardiac surgery. Crit Care. 2014;18:549.PubMedCentralPubMed Hincker A, Feit J, Sladen RN, Wagener G. Rotational thromboelastometry predicts thromboembolic complications after major non-cardiac surgery. Crit Care. 2014;18:549.PubMedCentralPubMed
91.
Zurück zum Zitat Dai Y, Lee A, Critchley LA, White PF. Does thromboelastography predict postoperative thromboembolic events? A systematic review of the literature. Anesth Analg. 2009;108:734–42.PubMed Dai Y, Lee A, Critchley LA, White PF. Does thromboelastography predict postoperative thromboembolic events? A systematic review of the literature. Anesth Analg. 2009;108:734–42.PubMed
92.
Zurück zum Zitat Yao X, Dong Q, Song Y, Wang Y, Deng Y, Li Y. Thrombelastography Maximal Clot Strength Could Predict One-Year Functional Outcome in Patients with Ischemic Stroke. Cerebrovasc Dis. 2014;38:182–90.PubMed Yao X, Dong Q, Song Y, Wang Y, Deng Y, Li Y. Thrombelastography Maximal Clot Strength Could Predict One-Year Functional Outcome in Patients with Ischemic Stroke. Cerebrovasc Dis. 2014;38:182–90.PubMed
93.
Zurück zum Zitat Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw Jr BW, et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg. 1985;64:888–96.PubMedCentralPubMed Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw Jr BW, et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg. 1985;64:888–96.PubMedCentralPubMed
94.
Zurück zum Zitat Francis JL, Francis DA, Gunathilagan GJ. Assessment of hypercoagulability in patients with cancer using the Sonoclot Analyzer and thromboelastography. Thromb Res. 1994;74:335–46.PubMed Francis JL, Francis DA, Gunathilagan GJ. Assessment of hypercoagulability in patients with cancer using the Sonoclot Analyzer and thromboelastography. Thromb Res. 1994;74:335–46.PubMed
95.
Zurück zum Zitat Akay OM, Ustuner Z, Canturk Z, Mutlu FS, Gulbas Z. Laboratory investigation of hypercoagulability in cancer patients using rotation thrombelastography. Med Oncol. 2009;26:358–64.PubMed Akay OM, Ustuner Z, Canturk Z, Mutlu FS, Gulbas Z. Laboratory investigation of hypercoagulability in cancer patients using rotation thrombelastography. Med Oncol. 2009;26:358–64.PubMed
96.
Zurück zum Zitat Spiezia L, Marchioro P, Radu C, Rossetto V, Tognin G, Monica C, et al. Whole blood coagulation assessment using rotation thrombelastogram thromboelastometry in patients with acute deep vein thrombosis. Blood Coagul Fibrinolysis. 2008;19:355–60.PubMed Spiezia L, Marchioro P, Radu C, Rossetto V, Tognin G, Monica C, et al. Whole blood coagulation assessment using rotation thrombelastogram thromboelastometry in patients with acute deep vein thrombosis. Blood Coagul Fibrinolysis. 2008;19:355–60.PubMed
97.
Zurück zum Zitat Koopman K, Uyttenboogaart M, Hendriks HG, Luijckx GJ, Cramwinckel IR, Vroomen PC, et al. Thromboelastography in patients with cerebral venous thrombosis. Thromb Res. 2009;124:185–8.PubMed Koopman K, Uyttenboogaart M, Hendriks HG, Luijckx GJ, Cramwinckel IR, Vroomen PC, et al. Thromboelastography in patients with cerebral venous thrombosis. Thromb Res. 2009;124:185–8.PubMed
98.
Zurück zum Zitat O’Donnell J, Riddell A, Owens D, Handa A, Pasi J, Hamilton G, et al. Role of the Thrombelastograph as an adjunctive test in thrombophilia screening. Blood Coagul Fibrinolysis. 2004;15:207–11.PubMed O’Donnell J, Riddell A, Owens D, Handa A, Pasi J, Hamilton G, et al. Role of the Thrombelastograph as an adjunctive test in thrombophilia screening. Blood Coagul Fibrinolysis. 2004;15:207–11.PubMed
99.
Zurück zum Zitat Miall FM, Deol PS, Barnes TA, Dampier K, Watson CC, Oppenheimer CA, et al. Coagulation status and complications of pregnancy. Thromb Res. 2005;115:461–7.PubMed Miall FM, Deol PS, Barnes TA, Dampier K, Watson CC, Oppenheimer CA, et al. Coagulation status and complications of pregnancy. Thromb Res. 2005;115:461–7.PubMed
100.
Zurück zum Zitat Sharma SK, Philip J, Wiley J. Thromboelastographic changes in healthy parturients and postpartum women. Anesth Analg. 1997;85:94–8.PubMed Sharma SK, Philip J, Wiley J. Thromboelastographic changes in healthy parturients and postpartum women. Anesth Analg. 1997;85:94–8.PubMed
101.
Zurück zum Zitat Steer PL, Krantz HB. Thromboelastography and Sonoclot analysis in the healthy parturient. J Clin Anesth. 1993;5:419–24.PubMed Steer PL, Krantz HB. Thromboelastography and Sonoclot analysis in the healthy parturient. J Clin Anesth. 1993;5:419–24.PubMed
102.
Zurück zum Zitat Della Rocca G, Dogareschi T, Cecconet T, Buttera S, Spasiano A, Nadbath P, et al. Coagulation assessment in normal pregnancy: thrombelastography with citrated non activated samples. Minerva Anestesiol. 2012;78:1357–64.PubMed Della Rocca G, Dogareschi T, Cecconet T, Buttera S, Spasiano A, Nadbath P, et al. Coagulation assessment in normal pregnancy: thrombelastography with citrated non activated samples. Minerva Anestesiol. 2012;78:1357–64.PubMed
103.
Zurück zum Zitat McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg. 2005;100:1576–83.PubMed McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg. 2005;100:1576–83.PubMed
104.
Zurück zum Zitat Kashuk JL, Moore EE, Sabel A, Barnett C, Haenel J, Le T, et al. Rapid thrombelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients. Surgery. 2009;146:764–72. discussion 772-764.PubMed Kashuk JL, Moore EE, Sabel A, Barnett C, Haenel J, Le T, et al. Rapid thrombelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients. Surgery. 2009;146:764–72. discussion 772-764.PubMed
105.
Zurück zum Zitat Evans PA, Hawkins K, Lawrence M, Williams RL, Barrow MS, Thirumalai N, et al. Rheometry and associated techniques for blood coagulation studies. Med Eng Phys. 2008;30:671–9.PubMed Evans PA, Hawkins K, Lawrence M, Williams RL, Barrow MS, Thirumalai N, et al. Rheometry and associated techniques for blood coagulation studies. Med Eng Phys. 2008;30:671–9.PubMed
106.
Zurück zum Zitat Antovic A. The overall hemostasis potential: a laboratory tool for the investigation of global hemostasis. Semin Thromb Hemost. 2010;36:772–9.PubMed Antovic A. The overall hemostasis potential: a laboratory tool for the investigation of global hemostasis. Semin Thromb Hemost. 2010;36:772–9.PubMed
107.
Zurück zum Zitat Simpson ML, Goldenberg NA, Jacobson LJ, Bombardier CG, Hathaway WE, Manco-Johnson MJ. Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults. Thromb Res. 2011;127:317–23.PubMed Simpson ML, Goldenberg NA, Jacobson LJ, Bombardier CG, Hathaway WE, Manco-Johnson MJ. Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults. Thromb Res. 2011;127:317–23.PubMed
108.
Zurück zum Zitat Matsumoto T, Nogami K, Shima M. Simultaneous measurement of thrombin and plasmin generation to assess the interplay between coagulation and fibrinolysis. Thromb Haemost. 2013;110:761–8.PubMed Matsumoto T, Nogami K, Shima M. Simultaneous measurement of thrombin and plasmin generation to assess the interplay between coagulation and fibrinolysis. Thromb Haemost. 2013;110:761–8.PubMed
109.
Zurück zum Zitat Fadeeva OA, Panteleev MA, Karamzin SS, Balandina AN, Smirnov IV, Ataullakhanov FI. Thromboplastin immobilized on polystyrene surface exhibits kinetic characteristics close to those for the native protein and activates in vitro blood coagulation similarly to thromboplastin on fibroblasts. Biochemistry (Mosc). 2010;75:734–43. Fadeeva OA, Panteleev MA, Karamzin SS, Balandina AN, Smirnov IV, Ataullakhanov FI. Thromboplastin immobilized on polystyrene surface exhibits kinetic characteristics close to those for the native protein and activates in vitro blood coagulation similarly to thromboplastin on fibroblasts. Biochemistry (Mosc). 2010;75:734–43.
110.
Zurück zum Zitat Dashkevich NM, Ovanesov MV, Balandina AN, Karamzin SS, Shestakov PI, Soshitova NP, et al. Thrombin activity propagates in space during blood coagulation as an excitation wave. Biophys J. 2012;103:2233–40.PubMedCentralPubMed Dashkevich NM, Ovanesov MV, Balandina AN, Karamzin SS, Shestakov PI, Soshitova NP, et al. Thrombin activity propagates in space during blood coagulation as an excitation wave. Biophys J. 2012;103:2233–40.PubMedCentralPubMed
111.
Zurück zum Zitat Ovanesov MV, Ananyeva NM, Panteleev MA, Ataullakhanov FI, Saenko EL. Initiation and propagation of coagulation from tissue factor-bearing cell monolayers to plasma: initiator cells do not regulate spatial growth rate. J Thromb Haemost. 2005;3:321–31.PubMed Ovanesov MV, Ananyeva NM, Panteleev MA, Ataullakhanov FI, Saenko EL. Initiation and propagation of coagulation from tissue factor-bearing cell monolayers to plasma: initiator cells do not regulate spatial growth rate. J Thromb Haemost. 2005;3:321–31.PubMed
112.
Zurück zum Zitat Panteleev MA, Ovanesov MV, Kireev DA, Shibeko AM, Sinauridze EI, Ananyeva NM, et al. Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively. Biophys J. 2006;90:1489–500.PubMedCentralPubMed Panteleev MA, Ovanesov MV, Kireev DA, Shibeko AM, Sinauridze EI, Ananyeva NM, et al. Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively. Biophys J. 2006;90:1489–500.PubMedCentralPubMed
113.
Zurück zum Zitat Dashkevich NM, Vuimo TA, Ovsepyan RA, Surov SS, Soshitova NP, Panteleev MA, et al. Effect of pre-analytical conditions on the thrombodynamics assay. Thromb Res. 2014;133:472–6.PubMed Dashkevich NM, Vuimo TA, Ovsepyan RA, Surov SS, Soshitova NP, Panteleev MA, et al. Effect of pre-analytical conditions on the thrombodynamics assay. Thromb Res. 2014;133:472–6.PubMed
114.
Zurück zum Zitat Soshitova NP, Karamzin SS, Balandina AN, Fadeeva OA, Kretchetova AV, Galstian GM, et al. Predicting prothrombotic tendencies in sepsis using spatial clot growth dynamics. Blood Coagul Fibrinolysis. 2012;23:498–507.PubMed Soshitova NP, Karamzin SS, Balandina AN, Fadeeva OA, Kretchetova AV, Galstian GM, et al. Predicting prothrombotic tendencies in sepsis using spatial clot growth dynamics. Blood Coagul Fibrinolysis. 2012;23:498–507.PubMed
115.
Zurück zum Zitat Urnova ES, Pokrovskaia OS, Gracheva MA, Vasil’ev SA, Gemdzhian EG, Tarandovskii ID, et al. [Hypercoagulation syndrome in multiple myeloma]. Ter Arkh. 2014;86:73–9.PubMed Urnova ES, Pokrovskaia OS, Gracheva MA, Vasil’ev SA, Gemdzhian EG, Tarandovskii ID, et al. [Hypercoagulation syndrome in multiple myeloma]. Ter Arkh. 2014;86:73–9.PubMed
116.
Zurück zum Zitat Seregina EA, Nikulina OF, Tsvetaeva NV, Rodionova MN, Gribkova IV, Orel EB, et al. Laboratory tests for coagulation system monitoring in a patient with beta-thalassemia. Int J Hematol. 2014;99:588–96.PubMed Seregina EA, Nikulina OF, Tsvetaeva NV, Rodionova MN, Gribkova IV, Orel EB, et al. Laboratory tests for coagulation system monitoring in a patient with beta-thalassemia. Int J Hematol. 2014;99:588–96.PubMed
117.
Zurück zum Zitat Gorog DA, Kovacs IB. Thrombotic status analyser. Measurement of platelet-rich thrombus formation and lysis in native blood. Thromb Haemost. 1995;73:514–20.PubMed Gorog DA, Kovacs IB. Thrombotic status analyser. Measurement of platelet-rich thrombus formation and lysis in native blood. Thromb Haemost. 1995;73:514–20.PubMed
118.
Zurück zum Zitat Suades R, Padro T, Vilahur G, Badimon L. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thromb Haemost. 2012;108:1208–19.PubMed Suades R, Padro T, Vilahur G, Badimon L. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thromb Haemost. 2012;108:1208–19.PubMed
119.
Zurück zum Zitat Shechter M, Merz CN, Paul-Labrador MJ, Kaul S. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol. 2000;35:300–7.PubMed Shechter M, Merz CN, Paul-Labrador MJ, Kaul S. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol. 2000;35:300–7.PubMed
120.
Zurück zum Zitat Roest M, Reininger A, Zwaginga JJ, King MR, Heemskerk JW. Flow chamber-based assays to measure thrombus formation in vitro: requirements for standardization. J Thromb Haemost. 2011;9:2322–4.PubMed Roest M, Reininger A, Zwaginga JJ, King MR, Heemskerk JW. Flow chamber-based assays to measure thrombus formation in vitro: requirements for standardization. J Thromb Haemost. 2011;9:2322–4.PubMed
121.
Zurück zum Zitat Woodle SA, Shibeko AM, Lee TK, Ovanesov MV. Determining the impact of instrument variation and automated software algorithms on the TGT in hemophilia and normalized plasma. Thromb Res. 2013;132:374–80.PubMed Woodle SA, Shibeko AM, Lee TK, Ovanesov MV. Determining the impact of instrument variation and automated software algorithms on the TGT in hemophilia and normalized plasma. Thromb Res. 2013;132:374–80.PubMed
122.
Zurück zum Zitat Loeffen R, Kleinegris MC, Loubele ST, Pluijmen PH, Fens D, van Oerle R, et al. Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method. J Thromb Haemost. 2012;10:2544–54.PubMed Loeffen R, Kleinegris MC, Loubele ST, Pluijmen PH, Fens D, van Oerle R, et al. Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method. J Thromb Haemost. 2012;10:2544–54.PubMed
123.
Zurück zum Zitat Dargaud Y, Wolberg AS, Luddington R, Regnault V, Spronk H, Baglin T, et al. Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study. Thromb Res. 2012;130:929–34.PubMed Dargaud Y, Wolberg AS, Luddington R, Regnault V, Spronk H, Baglin T, et al. Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study. Thromb Res. 2012;130:929–34.PubMed
Metadaten
Titel
Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk
verfasst von
Elena N Lipets
Fazoil I Ataullakhanov
Publikationsdatum
01.12.2015
Verlag
BioMed Central
Erschienen in
Thrombosis Journal / Ausgabe 1/2015
Elektronische ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-015-0038-0

Weitere Artikel der Ausgabe 1/2015

Thrombosis Journal 1/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.